Policy & News
Heavyweight! mRNA vaccine combination therapy reduces melanoma death risk by 65%!
2023-06-06
On 5 June, mRNA vaccine giants Moderna and Merck Sharp & Dohme announced at the 2023 ASCO Annual Meeting that a Phase 2b study of the combination of the individualised oncology vaccine, mRNA-4157 (V940), and the anti-PD-1 therapy, Keytruda, demonstrated that the combination therapy, used in patients with surgically resected, high-risk melanoma (Stage III/IV), reduced the risk of spreading or dying from this skin cancer by 65%, compared to Keytruda alone.
View More
2023-06-05
The Implementing Rules of the Regulations on Human Genetic Resources Management have been considered and adopted at the 3rd Ministerial Meeting of the Ministry of Science and Technology on 11 May 2023, and are hereby promulgated and shall come into force on 1 July 2023.
View More
World's 2nd RSV vaccine approved for marketing by FDA
2023-06-05
On 31 May, Pfizer announced that its bivalent respiratory syncytial virus (RSV) vaccine, ABRYSVO (RSVpreF, PF-06928316), has been approved for marketing by the FDA for the prevention of lower respiratory tract disease (LRTD) caused by RSV in people 60 years of age and older, making it the second RSV vaccine approved for marketing in the world.
View More
